NHS cleared to use Astellas' non-hormonal menopause drug
Around half a million women will soon be able to access Astellas' Veoza treatment for symptoms like hot flushes associated with menopause.
Vertex preps FDA filing for IgAN drug after phase 3 readout
Vertex's bid to expand beyond cystic fibrosis has taken a big step forward with phase 3 data for povetacicept in severe kidney disorder IgAN.
NICE says no to Genmab cervical cancer therapy
Genmab's recently approved therapy for relapsed cervical cancer has been turned down for NHS use in initial NICE guidance.
Veeva buys brand engagement firm Ostro for $100m
Veeva Systems has reached a $100m deal to acquire Ostro, which helps pharma connect with doctors and patients using AI-based conversational tools.
FDA approves leucovorin – but not for autism
The FDA stops short of approving leucovorin for autism, but will its clearance for ultra-rare condition CFD-FOLR1 lead to more off-label prescribing?
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
The Evolution Summit Announces May 2026 Program for Clinical...
marcus evans announces The Evolution Summit, taking place May 7-8, 2026 at The Ritz-Carlton, Fort Lauderdale, Florida.
PHARMAP 2026: Where Pharma Meets Policy
The Pharmaceutical Manufacturing and Packaging Congress (PHARMAP 2026)
7th Dermatology Drug Development Summit Europe
The Summit is a premier three-day industry event designed for senior leaders, clinical scientists, regulatory experts and commercial strategists
The PM Society Launches Pharmony to Support More Effective P...
The Pharmaceutical Marketing Society (PM Society) today announces the launch of Pharmony
EVERSANA Names Monica Avram Executive Vice President and Chi...
As chief legal officer and a member of the Executive Leadership Team, Monica Avram leads EVERSANA's global Legal and Compliance function.